shkreli was ceo of kalobios before he ran into trouble with a different deal.y will lower the cost to the cost of making it it plus a reasonable transparntd profit. >>> facebook starts its f8 conference today in ft. mason. taking a look at its payroll and it pays men and women equal for equal jobs. microsoft just announced the same. >>> all this comes on equal pay day. the day that women have to work to from last year to make what a man made in 2015. now, that statistic is up for a lot of debate, but, nonetheless, we know unequal pay is a problem. a study by job placement firm hired said job negotiation husband a big effect. the average male candidate just asks for more money and 70% of the time he gets it. in the san francisco bay area in high tech women expect on average $124,000. men $136,000. though, keep in mind, this is broadly for tech not comparing jobs to jobs. gender and pay for what it is worth as a woman says her studies show men and women start equally out of college and they equal until it's time to raise a family and then things get off track. an

with shkreli out they are lowering the cost of the drug. the company won't say it's because shkreli is gone, they only say "the new pricing model is reflective of the new direction of the company." >>> facebook semi annual conference f8 starts in ft. mason in san francisco. mark zuckerberg will deliver the keynote speech today at 10:00. users are not updating their own timelines with personal stuff. there are too many articles about donald trump and not enough vacation pictures. >>> equal pay about facebook and microsoft. according to their payroll departments women are paid just as much as men for the same job in their companies. certainly that is not true everywhere. we'll take a look at why coming up at 6:00. >>> ouch. for those of you who work in construction and other trades, a warning this morning about crew cabs the insurance institute for highway safety has tested the number of these crew and extended cab pickups. there are pickups with extra doors and the back seat. not as safe as you might hope. the ford f-150 gets a good rating.

same thing with martin shkreli, am i saying his name right? liz: shkreli. the hoodie ceo. >> right.. you know, he got nailed and he's accused of creating some sort of a ponzi scheme or pyramid scheme within a hedge fund -- liz: he wasn't nailed for the price hike. >> no. that's what i'm saying. what is pearson going to be grilled on before this committee? moral issues. is it, you know, it is going to be a lot of that, a lot of preening about drug pricing. you know, listen, the public will get an education on the law here, but if you think this guy's going to go to jail over this, not one person tells me that. they tell me what he did was completely, totally legal. you may not like the ethics, but that's the legal -- remember: drug pricing and this industry, highly, highly regulated industry. liz: it had a nice move last week, it is down today. >> it had a nice move on our story, apparently, about them possibly spinning off at least part of their bausch and loam subsidiary. ackman said they don't want to sell it. don't believe him. that is on the table. it's clearly something they're

we have to keep our eyes on martin shkreli who somehow beat out bill cosby in the first round. >> yepon to crush old people in the second round! they are very brittle, roy. >> now hasan faces his toughest challenge yet when he squares off against the united states congress. >> ooh, okay. and this game and in real life, they're going to head to head. this is an interesting matchup on a philosophical level, roy. are people madder about one specific asshole or a whole building of assholes? >> congress is like a costco of assholes. more assholes than anyone could ever need! (cheers and applause) just pallets of assholes. you bring home a 50 500 pack of assholes and you're like what in the hell am ill going to go with all these assholes? you call your friends, hey, got some assholes... >> i will still give it to you on this but it's about quality over quantity, roy. let's move to the issues region where global warming is facing off head to head with homophobia. these are two things we should all be mad about especially if you're this gay polar bear. how is he going to vote? on the one hand

you look at martin shkreli getting away with what he got away with and he's a guy. look at mike pierson, he's a guy. i do think it has to do with smoke screens and people not doing their homework and due diligence and not gender on this -- >> to that point -- quickly, bill. >> well, i would say that -- before -- >> hold on, guys. hold on, guys. let me ask les a question here since we have this little moment here. >> what ripple effect does this have on funding other biotech companies out there in silicon valley, does this gum up the works, make people question every single slide show that is presented to them about the wonders of whatever new process the company claims to have. >> absolutely. it should. i think jeff's point and the snake oil sold and the valuations sold without a lot of diligence, i think a lot of this is going to come home to roost over time and i think a lot of people invested just because of famous names. it is not just health care. a lot of it in technology too. i think we're going to see more of these kinds of blowups. maybe not to the same ext

andrew bacevich, you have called donald trump, said he is to american politics what martin shkreli iso big pharma. explain. >> i think he is the same sort of -- his attitude is the same sort of smirking cynicism that we s saw in a form suitable scandal -- pharmaceutical scandal. i haveve a five year oldld grann who i love dearly, a and he is a wowonderful boy. he also has a tendency to blurt out whatever happens to be passing through his mind. it seems t to me that donald trp , who is not five years old, suffers from the same sort of inclinination. be angests that he would enormously dangerous commander-in-chief. i think we all recognize people say things on the campaign trail that may not actually reflect their intentionss were they to e an office, but there does come -- there are moments when the gap tween what is being said and what ought to be done by any responsible person, when that theis so broad that rhetoric itself i think becomes a disqualifying factor. add, it isquickly not clear to me that senator cruz, who is the apparent alternative, is by any inclination any better. if

mccaskill: i was involved in another investigation, where martin shkreli found a limited market for a drug, and jacked the price up. maybe we need to take a page out of his book and jack the price down. figure the price of the drug we pay to develop, and continue to manufacture it ourselves, and drive the cost way down. because now we are taking out privateess that the company is making from our investment. i don't think the private company should be able -- it seems weird that we are making the investment, that is the type of deal -- deal that any businessman with like to get. dr. hatchett: yes, we are always looking for ways we can be better spending the taxpayers money. we recognize our responsibility, and we do provide a great deal of that on -- upfront investment. sen. mccaskill: i would like you to take a look at that, because i'm not sure that makes sense for the taxpayers. carper: i want to come back to mr. shea briefly. with regards to the avian influenza outbreak. a number of states were hit especially turkeys, and lay hands. we saw that in november of 2014, and last year. t

the other kid, martin shkreli did not get charged. neil: but it's legal. it's a little insulting. >> it looks legal, but we don't know. there's been a lot of investigation with their relationship with the distributor are some of the drugs. so as we first reported, they are discussing selling off assets, including no matter what they say, no matter what bill ackman says, they are talking internally about selling either all of it or piece of bausch & lomb. they all met eye care company. neil: the issue about how far a drug company can go. is it ascends that these kind of incidents -- >> it does. here's the thing with the company. if you set a company not to go on and do r&d, if you set up a company rolling up other companies in jacking up prices. neil: we are the new guys in town. we take over the cancer drug. >> by the way, we will hear what michael pearson has to say, the ceo. if you do something like that, you'll come up with a lot of pressure. drugs is highly regulated industry. >> there is a bull case for the stock, by the way. they are going to sell of

mccaskill: i was involved in another investigation, where martin shkreli found a limited market for arug, and jacked the price up. maybe we need to take a page out of his book and jack the price down. figure the price of the drug we pay to develop, and continue to manufacture it ourselves, and drive the cost way down. because now we are taking out privateess that the company is making from our investment. i don't think the private company should be able -- it seems weird that we are making the investment, that is the type of deal -- deal that any businessman with like to get. dr. hatchett: yes, we are always looking for ways we can be better spending the taxpayers money. we recognize our responsibility, and we do provide a great deal of that on -- upfront investment. sen. mccaskill: i would like you to take a look at that, because i'm not sure that makes sense for the taxpayers. carper: i want to come back to mr. shea briefly. with regards to the avian influenza outbreak. a number of states were hit especially turkeys, and lay hands. we saw that in november of 2014, and last year. to

we now have a situation after judge shkreli a's passing, that it is not just that the republican majority in the senate intend to vote against a highly qualified judge. we now have a situation saying we simply will not consider the nomination itself to we will just shut down the process. as a consequence, we have a four quart tie on the supreme court -- four-court tie on the supreme court. this vacancy will remain. that is unprecedented. not only are they willing to -- not willing to hold a vote at this point, they are not holding hearings on judge garland and on some cases, mitchell -- mitch mcconnell and others have said we will not even show the courtesy of meeting with the judge to find out what he thinks. and i think what is important for all of you to understand, because you're going to be not just lawyers appearing in court, potentially, what custodians of our legal system and democracy, is if you start getting into a situation in which the process of appointing judges is so partisan, that in imminently qualified jurist , then even get a hearing we are going to see the kinds of >>

this is all a long lasting overreaction to the overpricing that was done by martin shkreli.d with hillary already mentioning desire to clamp down on drug prices the whole market very sensitive. when you get a rejection from the fda people will overreact. united therapeutics has a strong track record of turning around first reaction into an approval. >> what do you have to do to turn it around? >> we provide information that the fda has asked for and they ask for this information very reasonably. you may recall our last drug approved was turned down by fda twice before it was approved and then the stock skyrocketed. this case more complicated because we have to cooperate with medtronic to bring all the information to the fda that they want. we'll do that and this drug delivery advice will be approved. >> what are they asking >> they are asking for long term quality assurance and quality control of the miniature pump. this is the first time in history that a little pump placeed into the cardiovascular space would deliver medicine 24 hours a day, 365 days a year. the fda wants

we are talking about martin shkreli and players like valeant who have gotten into markets where they'ven come in and compete with them. there's valid situations from bad actors that play into this. >> some of these instances also occurred because commercial drug plans were not watching what they were paying for. they were letting the smaller products get increased dramatically, and they were only focusing on the high-volume products. i think the big sign that's occurred now for the -- the big signal, is that, if i am a commercial drug plan, i should be watching out for the smaller ones that are also going up like crazy. and i think there has been a big change in the last year. you are going to see a totally different picture going forward. the other thing that's changed quite a bit is the fda has become more sensitive to these shortages. >> fred, thank you. this was a great hour. thank you for helping us through it. >> thank you very much. >> i really appreciated our two hours together, fred. >>> when we return decision 2016. five key primaries today. they could be make or break for man